Literature DB >> 22333754

Longitudinally extensive transverse myelitis as the sole presentation of neuro-Behçet's disease responding to infliximab.

Ian Coulter1, Saif Huda, Atik Baborie, Anu Jacob.   

Abstract

CONTEXT: Isolated involvement of the spinal cord is an uncommon presentation of neuro-Behçet's disease (NBD) and it is associated with a poor prognosis for functional recovery.
METHOD: A case report of an 18-year-old Turkish man who presented with a progressive paraparesis and bladder dysfunction secondary to a longitudinally extensive transverse myelitis as the sole presentation of NBD.
FINDINGS: Examination revealed a spastic paraparesis and a T7 sensory level. Magnetic resonance imaging revealed multiple enhancing lesions throughout the thoracic cord and cerebrospinal fluid showed intense neutrophilia. On further enquiry a family history of Behçet's disease was elicited. The patient subsequently reported a history of recurrent oral ulceration and intermittent occular inflammation. A diagnosis of NBD was made and intravenous high-dose steroids commenced with poor response. In view of the poor prognosis for functional recovery associated with spinal NBD the patient was treated with infliximab, an anti-tumour necrosis factor-alpha monoclonal antibody, leading to excellent recovery of function. CONCLUSION/CLINICAL RELEVANCE: Early treatment with infliximab may facilitate a favourable functional recovery and should be considered in cases of NBD with spinal cord involvement.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22333754      PMCID: PMC3304557          DOI: 10.1179/2045772311Y.0000000050

Source DB:  PubMed          Journal:  J Spinal Cord Med        ISSN: 1079-0268            Impact factor:   1.985


  13 in total

1.  Multifocal myelitis in Behçet's disease.

Authors:  Susanna Moskau; Horst Urbach; Alexander Hartmann; Stephan Schmidt
Journal:  Neurology       Date:  2003-02-11       Impact factor: 9.910

Review 2.  Behçet's syndrome: disease manifestations, management, and advances in treatment.

Authors:  Hasan Yazici; Izzet Fresko; Sebahattin Yurdakul
Journal:  Nat Clin Pract Rheumatol       Date:  2007-03

Review 3.  Adalimumab (Humira™): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology.

Authors:  Piergiorgio Neri; Manuela Zucchi; Pia Allegri; Marta Lettieri; Cesare Mariotti; Alfonso Giovannini
Journal:  Int Ophthalmol       Date:  2011-02-02       Impact factor: 2.031

Review 4.  Infliximab for the treatment of Neuro-Behçet's disease: a case series and review of the literature.

Authors:  Nicolò Pipitone; Ignazio Olivieri; Angela Padula; Salvatore D'angelo; Angelo Nigro; Giulio Zuccoli; Luigi Boiardi; Carlo Salvarani
Journal:  Arthritis Rheum       Date:  2008-02-15

Review 5.  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.

Authors: 
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

6.  Cytokines in Behçet's disease.

Authors:  N Sayinalp; O I Ozcebe; O Ozdemir; I C Haznedaroğlu; S Dündar; S Kirazli
Journal:  J Rheumatol       Date:  1996-02       Impact factor: 4.666

7.  Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. The Neuro-Behçet Study Group.

Authors:  G Akman-Demir; P Serdaroglu; B Tasçi
Journal:  Brain       Date:  1999-11       Impact factor: 13.501

Review 8.  Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients.

Authors:  Aikaterini Arida; Kalliopi Fragiadaki; Eirini Giavri; Petros P Sfikakis
Journal:  Semin Arthritis Rheum       Date:  2010-12-17       Impact factor: 5.532

9.  The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center.

Authors:  Emire Kural-Seyahi; Izzet Fresko; Nurhan Seyahi; Yilmaz Ozyazgan; Cem Mat; Vedat Hamuryudan; Sebahattin Yurdakul; Hasan Yazici
Journal:  Medicine (Baltimore)       Date:  2003-01       Impact factor: 1.889

Review 10.  Neuro-Behçet's disease: epidemiology, clinical characteristics, and management.

Authors:  Adnan Al-Araji; Desmond P Kidd
Journal:  Lancet Neurol       Date:  2009-02       Impact factor: 44.182

View more
  9 in total

1.  Recurrent longitudinal extensive transverse myelitis in a neuro-Behçet syndrome treated with infliximab.

Authors:  Uğur Uygunoğlu; Maarya Pasha; Sabahattin Saip; Aksel Siva
Journal:  J Spinal Cord Med       Date:  2014-03-28       Impact factor: 1.985

Review 2.  Behçet's Syndrome and Nervous System Involvement.

Authors:  Uğur Uygunoğlu; Aksel Siva
Journal:  Curr Neurol Neurosci Rep       Date:  2018-05-23       Impact factor: 5.081

3.  Solitary sclerosis: Progressive neurological deficit from a spatially isolated demyelinating lesion: A further report.

Authors:  Devipriya Rathnasabapathi; Liene Elsone; Anita Krishnan; Carolyn Young; Andrew Larner; Anu Jacob
Journal:  J Spinal Cord Med       Date:  2015-01-23       Impact factor: 1.985

4.  Acute necrotizing encephalopathy (ANE1): rare autosomal-dominant disorder presenting as acute transverse myelitis.

Authors:  Katharina Wolf; Thomas Schmitt-Mechelke; Spyridon Kollias; Armin Curt
Journal:  J Neurol       Date:  2013-01-18       Impact factor: 4.849

5.  Longitudinally extensive transverse myelitis with intramedullary metastasis of small-cell lung carcinoma: an autopsy case report.

Authors:  Kenya Nishioka; Ryota Tanaka; Satoshi Tsutsumi; Hideki Shimura; Yutaka Oji; Harumi Saeki; Yukimasa Yasumoto; Masanori Ito; Nobutaka Hattori; Takao Urabe
Journal:  Case Rep Neurol Med       Date:  2013-12-22

6.  Efficacy of infliximab in neuro-Behçet's disease presenting with isolated longitudinally extensive transverse myelitis.

Authors:  Ryo Kuroda; Junko Suzuki; Mizuho Muramatsu; Asami Tasaki; Mariko Yano; Noboru Imai; Masahiro Serizawa; Masahiro Kobari
Journal:  J Neurol       Date:  2013-11-01       Impact factor: 4.849

Review 7.  Off-label uses of anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis.

Authors:  Daniel Sánchez-Cano; José Luis Callejas-Rubio; Ricardo Ruiz-Villaverde; Raquel Ríos-Fernández; Norberto Ortego-Centeno
Journal:  Mediators Inflamm       Date:  2013-08-01       Impact factor: 4.711

8.  Infliximab is a plausible alternative for neurologic complications of Behçet disease.

Authors:  Burcu Zeydan; Ugur Uygunoglu; Sabahattin Saip; Onat N Demirci; Emire Seyahi; Serdal Ugurlu; Vedat Hamuryudan; Aksel Siva; Orhun H Kantarci
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-07-08

Review 9.  Clinical and imaging features of spinal cord type of neuro Behçet disease: A case report and systematic review.

Authors:  Hui-Miao Liu; Ci Dong; Yong-Zhi Zhang; Ya-Yun Tian; Hong-Xu Chen; Sai Zhang; Na Li; Ping Gu
Journal:  Medicine (Baltimore)       Date:  2017-10       Impact factor: 1.889

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.